Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOU064 long-term extension study in chronic spontaneous urticaria
NL-OMON49297Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of remibrutinib in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Novartis. Planned start Nov 2019; status: withdrawn.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON49297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49297.